Genetic factors associated with the treatment response to reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy

Abstract

Purpose : To investigate genetic factors associated with the treatment response to reduced-fluence photodynamic therapy (RFPDT) for chronic central serous chorioretinopathy (cCSC).

Methods : This was a retrospective study of 85 eyes from 85 patients with cCSC who underwent RFPDT and were followed up for more than 12 months. Patients were divided into good response group (54 patients in group A) and poor response group (31 patients in group B) based on either persistence or recurrence of subretinal fluid detected by spectral domain optical coherence tomography after first RFPDT. Genotyping of four single nucleotide polymorphisms (SNPs), including age-related maculopathy susceptibility (ARMS2) A69S (rs10490924), complement factor H (CFH) I62V (rs800292), CFH Y402H (rs1061170) and CFH (rs1329428) was conducted using TaqMan technology.

Results : There were no significant differences in baseline characteristics including sex, age and best corrected logMAR visual acuity between groups. However, there was a significant difference in T-allele frequency in ARMS2 A69S (rs10490924) between groups (24.5% in group A, 40.3% in group B, p=0.032).

Conclusions : ARMS2 variants might be associated with the treatment response of RFPDT in cCSC patients.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.